Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
Total Valuation
Phathom Pharmaceuticals has a market cap or net worth of $286.21M. The enterprise value is $834.57M.
Market Cap$286.21M
Enterprise Value$834.57M
Share Statistics
Phathom Pharmaceuticals has 69.64M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding69.64M
Owened by Insiders18.29%
Owened by Instutions0.11%
Financial Efficiency
Phathom Pharmaceuticals’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee$129,395.785
Profits Per Employee-$782,964.871
Employee Count427
Asset Turnover0.15
Inventory Turnover2.49
Valuation Ratios
The current PE Ratio of Phathom Pharmaceuticals is -1.53. Phathom Pharmaceuticals’s PEG ratio is -0.04.
PE Ratio-1.53
PS Ratio9.28
PB Ratio-2.02
Price to Fair Value-2.02
Price to FCF-1.92
Price to Operating Cash Flow-1.92
PEG Ratio-0.04
Income Statement
In the last 12 months, Phathom Pharmaceuticals had revenue of $55.25M and earned -$334.33M in profits. Earnings per share was -$5.35.
Revenue$55.25M
Gross Profit$47.28M
Operating Income-$277.47M
Pretax Income-$334.33M
Net Income-$334.33M
EBITDA-261.52M
Earnings Per Share (EPS)-5.35
Cash Flow
In the last 12 months, operating cash flow was -$266.77M and capital expenditures -$5.00K, giving a free cash flow of -$266.77M billion.
Operating Cash Flow-$266.77M
Free Cash Flow-$266.77M
Free Cash Flow per Share-$3.83
Dividends & Yields
Phathom Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.70
52-Week Price Change-51.30%
50-Day Moving Average5.51
200-Day Moving Average10.63
Relative Strength Index (RSI)41.95
Average Volume (3m)1.41M
Important Dates
Phathom Pharmaceuticals upcoming earnings date is May 13, 2025, Before Open.
Last Earnings DateMar 6, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Phathom Pharmaceuticals as a current ratio of 4.20, with Debt / Equity ratio of >-0.01
Current Ratio4.20
Quick Ratio4.16
Debt to Market Cap<0.01
Net Debt to EBITDA―
Interest Coverage Ratio-3.85
Taxes
In the past 12 months, Phathom Pharmaceuticals has paid $170.72K in taxes.
Income Tax$170.72K
Effective Tax Rate0.00%
Enterprise Valuation
Phathom Pharmaceuticals EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Phathom Pharmaceuticals has $297.26M in cash and marketable securities with $201.91M in debt, giving a net cash position of -$95.35M billion.
Cash & Marketable Securities$297.26M
Total Debt$201.91M
Net Cash-$95.35M
Net Cash Per Share-$1.37
Tangible Book Value Per Share-$4.01
Margins
Gross margin is 85.57%, with operating margin of -502.18%, and net profit margin of -605.09%.
Gross Margin85.57%
Operating Margin-502.18%
Pretax Margin-605.09%
Net Profit Margin-605.09%
EBITDA Margin-473.33%
EBIT Margin-474.76%
Analyst Forecast
The average price target for Phathom Pharmaceuticals is $21.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$21.43
Price Target Upside339.14%
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast8001.47%
EPS Growth Forecast-37.69%